Dialysis News and Research

Latest Dialysis News and Research

Celgene receives Japan's MHLW approval for REVLIMID in deletion 5q myelodysplastic syndrome patients

Celgene International Sàrl announced that REVLIMID (lenalidomide) has been granted full marketing authorization by Japan's Ministry of Health, Labour and Welfare (MHLW) for the treatment of patients with myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenic abnormality. REVLIMID was also approved in June 2010 in combination with dexamethasone, for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior standard therapy.

20 Aug 2010

Donor kidneys from deceased as good as those from brain-dead: Study

According to a new study from the UK, transplanted kidneys from patients whose hearts have stopped perform just as well as those from patients who are brain-dead but still alive. The former have been earlier considered to be weaker since the heart had stopped pumping blood into them before transplant. The study was published online by the The Lancet.

20 Aug 2010

70% rise in kidney disease in Australia over past 7 years: Report

According to a report released today by the Australian Institute of Health and Welfare (AIHW), with the rise of type II diabetes patients, there is increasing number of hospitalizations related to chronic kidney disease in Australia.

18 Aug 2010

FDA grants orphan drug designation to NephRx's lead product NX001

NephRx Corporation today announced that the U.S. Food and Drug Administration has granted orphan drug designation to its lead product NX001 for the prevention of delayed graft function in renal transplant recipients. NX001 is a kidney growth factor peptide that has demonstrated good safety and promising efficacy in two animal models of acute renal failure.

18 Aug 2010

Policies, practices concerning MRSA differ among acute-care hospitals in the U.S.: Researchers

Hospitals vary in how they detect and treat drug-resistant staph infections, but most follow national guideline recommendations, according to researchers at the University of Illinois at Chicago.

18 Aug 2010

Trauma center care cost-effective for all patients: Report

Trauma center care not only saves lives, it is a cost-effective way of treating major trauma, according to a new report from the Johns Hopkins Bloomberg School of Public Health's Center for Injury Research and Policy. Although treatment at a trauma center is more expensive, the benefits of this approach in terms of lives saved and quality of life-years gained outweigh the costs. The study finds that the added cost of treatment at a trauma center versus nontrauma center is only $36,319 for every life-year gained or $790,931 per life saved.

18 Aug 2010

ImPACKD, The Kidney Foundation of Canada launch online resource for CKD patients

Before today, millions of Canadians living with chronic kidney disease did not have a strong online advocacy presence. Improving Patient Advocacy in Chronic Kidney Disease and The Kidney Foundation of Canada are now joining forces to provide an effective resource. Together, they are launching www.impackd.ca, a microsite of www.kidney.ca that is specifically designed for Canadians affected by chronic kidney disease.

17 Aug 2010

Mesa Labs first-quarter fiscal 2011 GAAP net income increases 29% to $1.32 million

Mesa Laboratories, Inc. today reported a fifty percent increase in revenue for the fiscal first quarter ended June 30, 2010.

16 Aug 2010

American CareSource second-quarter revenues decrease to $16.0 million

American CareSource Holdings Inc. today announced second quarter 2010 revenues of $16.0 million compared to $17.1 million in the corresponding prior year quarter. Net income for the second quarter 2010 was $299,000, or $0.02 per diluted share, compared to $534,000, or $0.01 per diluted share, in the corresponding prior year quarter. Net income for the second quarter 2010 included a federal income tax provision of $137,000, or $0.01 per diluted share, which was not included in net income for the second quarter 2009.

13 Aug 2010

Kibow to support KDAE week for educating policymakers about kidney disease

Kibow Biotech would like to show its support for Kidney Disease Awareness and Education (KDAE) Week 2010, organized by American Nephrology Nurses' Association (ANNA). Kidney Disease Awareness and Education Week is a week dedicated to educating policymakers and their staff members about the needs of patients suffering from or at risk for end stage renal disease (ESRD).

13 Aug 2010

Gore announces first implantation in IDE clinical study of ACUSEAL Vascular Graft in hemodialysis patients

W. L. Gore & Associates reported that the first patient, in an Investigational Device Exemption (IDE) clinical study evaluating the self sealing GORE® ACUSEAL Vascular Graft in patients on hemodialysis, has been surgically implanted with the device. The successful surgical procedure was performed on July 29, 2010 at Greenville Hospital System in Greenville, South Carolina. Less than 24 hours after the device was implanted it was successfully cannulated or punctured for initial hemodialysis access.

13 Aug 2010

Tengion announces clinical, corporate and second-quarter financial updates

Tengion Inc. today provided a corporate and product development update and reported its financial results for the quarter ended June 30, 2010.

12 Aug 2010

AACN endorses new clinical practice guidelines developed by Renal Physicians Association

The American Association of Critical-Care Nurses (AACN) recently endorsed the clinical practice guideline, "Shared Decision Making in the Appropriate Initiation of and Withdrawal from Dialysis," developed by Renal Physicians Association (RPA), Rockville, Md.

11 Aug 2010

Cardiovascular Systems fourth-quarter revenue increases 15% to $18.0 million

Cardiovascular Systems, Inc., a medical device company developing and commercializing innovative interventional treatment systems for vascular disease, today reported financial results for its fiscal fourth quarter and year ended June 30, 2010.

11 Aug 2010

Hemodialysis with AVF depends on patient’s health insurance: Study

Kidney disease patients insured by some federally sponsored national health care organizations are more likely to undergo an important predialysis procedure than patients with other types of insurance, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN). The results may provide insights into ways to improve kidney-related care for patients before they go on dialysis.

10 Aug 2010

Pay-for-performance makes its way into dialysis clinics

Chattanooga (Tenn.) Times Free Press: A new Medicare rule may ding dialysis centers by up to two percent of their reimbursement in 2012 if they don't meet quality standards the agency sets. The program "is the agency's first pay-per-performance system, and it won't be the last." The agency has, however, run various experiments that pay providers for better performance.

10 Aug 2010

Donate Life California's list of organ and tissue donors increases to seven million

The number of registered organ and tissue donors in California has reached the nation-leading seven million mark, it was announced today by California Assembly Speaker John A. Pérez (D-Los Angeles), the Donate Life California Organ & Tissue Donor Registry, and the California Department of Motor Vehicles.

7 Aug 2010

Research shows variations in care that kidney disease patients receive before starting dialysis

The wealth or poverty of kidney disease patients' communities impacts the quality of care patients receive before starting dialysis, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology. The results suggest that medical professionals need to improve care for patients who have not yet started dialysis.

6 Aug 2010

Affymax, Takeda announce preliminary strategy for Hematide to treat anemia in chronic renal failure patients

Affymax, Inc. and Takeda Pharmaceutical Company Limited, today announced that the companies have decided on a preliminary strategic path forward for the investigational drug, Hematide™/peginesatide, for the treatment of anemia in chronic renal failure patients in the United States.

5 Aug 2010

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

Merck reported that two pivotal Phase III registration studies for boceprevir, its investigational oral hepatitis C protease inhibitor, have been completed and met the primary endpoints: in both studies in patients with chronic hepatitis C virus (HCV) genotype 1 infection, the addition of boceprevir to treatment with PEGINTRON® and REBETOL® significantly increased the number of patients who achieved sustained virologic response, compared to control groups that received Peg/riba plus placebo.

5 Aug 2010

Dialysis News and Research

Latest Dialysis News and Research

Celgene receives Japan's MHLW approval for REVLIMID in deletion 5q myelodysplastic syndrome patients

Donor kidneys from deceased as good as those from brain-dead: Study

70% rise in kidney disease in Australia over past 7 years: Report

FDA grants orphan drug designation to NephRx's lead product NX001

Policies, practices concerning MRSA differ among acute-care hospitals in the U.S.: Researchers

Trauma center care cost-effective for all patients: Report

ImPACKD, The Kidney Foundation of Canada launch online resource for CKD patients

Mesa Labs first-quarter fiscal 2011 GAAP net income increases 29% to $1.32 million

American CareSource second-quarter revenues decrease to $16.0 million

Kibow to support KDAE week for educating policymakers about kidney disease

Gore announces first implantation in IDE clinical study of ACUSEAL Vascular Graft in hemodialysis patients

Tengion announces clinical, corporate and second-quarter financial updates

AACN endorses new clinical practice guidelines developed by Renal Physicians Association

Cardiovascular Systems fourth-quarter revenue increases 15% to $18.0 million

Hemodialysis with AVF depends on patient’s health insurance: Study

Pay-for-performance makes its way into dialysis clinics

Donate Life California's list of organ and tissue donors increases to seven million

Research shows variations in care that kidney disease patients receive before starting dialysis

Affymax, Takeda announce preliminary strategy for Hematide to treat anemia in chronic renal failure patients

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Dialysis News and Research

Latest Dialysis News and Research

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Newsletters you may be interested in